{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "CYRAN"}]}, "abstract": null, "type_of_material": "News", "word_count": "384", "lead_paragraph": "The drug maker\u2019s offer for Synageva has a huge 136 percent premium. Still, exchanging a chunk of high-priced paper for assets may be a savvy move.", "pub_date": "2015-05-07T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Alexion Puts Its Soaring Stock Price to Good Use", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "snippet": "The drug maker\u2019s offer for Synageva has a huge 136 percent premium. Still, exchanging a chunk of high-priced paper for assets may be a savvy move.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/05/07/business/dealbook/alexion-puts-its-soaring-stock-price-to-good-use.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Alexion Pharmaceuticals Inc", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}], "blog": [], "_id": "554ab8da38f0d85a643468ce", "source": "The New York Times"}